Compare MNMD & FPF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNMD | FPF |
|---|---|---|
| Founded | 2019 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | N/A | N/A |
| Metric | MNMD | FPF |
|---|---|---|
| Price | $13.44 | $18.78 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $30.33 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 186.7K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.08% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.70 | $13.91 |
| 52 Week High | $14.43 | $18.09 |
| Indicator | MNMD | FPF |
|---|---|---|
| Relative Strength Index (RSI) | 58.52 | 62.51 |
| Support Level | $12.70 | $18.53 |
| Resistance Level | $14.28 | $18.63 |
| Average True Range (ATR) | 0.70 | 0.12 |
| MACD | 0.10 | 0.04 |
| Stochastic Oscillator | 62.28 | 97.44 |
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
First Trust Inter Dur Pref& Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek a high level of current income. Further, it has a secondary objective of capital appreciation. The Fund invests in the traditional preferred securities, hybrid preferred securities, floating rate & fixed-to-floating rate preferred securities, debt securities, convertible securities, and contingent convertible securities issued by U.S. and non-U.S. companies. Its investment portfolio includes industries such as Banks, Insurance, Capital Markets, Electric Utilities, Oil, Gas & Consumable Fuels, Food Products, and others.